AR069554A1 - Compuesto triciclico de amino benzoimidazol - Google Patents
Compuesto triciclico de amino benzoimidazolInfo
- Publication number
- AR069554A1 AR069554A1 ARP080105263A ARP080105263A AR069554A1 AR 069554 A1 AR069554 A1 AR 069554A1 AR P080105263 A ARP080105263 A AR P080105263A AR P080105263 A ARP080105263 A AR P080105263A AR 069554 A1 AR069554 A1 AR 069554A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- amino
- benzoimidazol
- syndrome
- salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 title 1
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000012904 Bartter disease Diseases 0.000 abstract 1
- 208000010062 Bartter syndrome Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000016998 Conn syndrome Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000019025 Hypokalemia Diseases 0.000 abstract 1
- -1 amino benzoimidazole compound Chemical class 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000024896 potassium deficiency disease Diseases 0.000 abstract 1
- 208000013846 primary aldosteronism Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1477607P | 2007-12-19 | 2007-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069554A1 true AR069554A1 (es) | 2010-02-03 |
Family
ID=40430143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105263A AR069554A1 (es) | 2007-12-19 | 2008-12-03 | Compuesto triciclico de amino benzoimidazol |
Country Status (33)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
| EA201000948A1 (ru) | 2007-12-19 | 2011-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы вирусной полимеразы |
| WO2010104721A1 (en) * | 2009-03-12 | 2010-09-16 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
| EP2977084B1 (en) | 2010-05-10 | 2017-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| WO2011157798A1 (en) | 2010-06-16 | 2011-12-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for stimulating reepithelialisation during wound healing |
| CN102060670A (zh) * | 2011-01-04 | 2011-05-18 | 常州大学 | 一种2-溴-6-氟苯甲醇的制备方法 |
| NZ712949A (en) | 2013-05-02 | 2017-04-28 | Pfizer | Imidazo-triazine derivatives as pde10 inhibitors |
| AR099416A1 (es) | 2014-02-28 | 2016-07-20 | Lilly Co Eli | Terapia combinada para la hipertensión resistente |
| SI3160948T1 (sl) | 2014-06-30 | 2020-06-30 | Astrazeneca Ab | Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida |
| NZ730759A (en) * | 2014-11-21 | 2018-10-26 | Lilly Co Eli | 1,2-benzothiazole compounds for the treatment of kidney disorders |
| EP3362095B1 (en) | 2015-10-13 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| ES2973248T3 (es) | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
| MA45202B1 (fr) * | 2016-09-24 | 2022-04-29 | Kbp Biosciences Co Ltd | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation |
| WO2021180818A1 (en) | 2020-03-11 | 2021-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072756A (en) * | 1973-05-17 | 1978-02-07 | Sandoz Ltd. | Tricyclo piperidino ketones and soporific compositions thereof |
| SE426341C (sv) * | 1980-02-14 | 1985-09-23 | Fagersta Ab | Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser |
| FR2603713B1 (fr) * | 1986-09-10 | 1992-07-24 | Canon Kk | Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant |
| US4999363A (en) * | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| GB8914061D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| US5378701A (en) * | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
| AR014195A1 (es) | 1997-12-29 | 2001-02-07 | Ortho Mcneil Pharm Inc | Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos |
| JP2002541144A (ja) | 1999-01-26 | 2002-12-03 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 医薬的に活性のある化合物及びその使用方法 |
| PL403800A1 (pl) * | 2001-11-21 | 2013-08-19 | Millennium Pharmaceuticals, Inc. | Kompozycja farmaceutyczna |
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| WO2005066153A1 (en) | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| CN1918151A (zh) | 2003-12-19 | 2007-02-21 | 伊莱利利公司 | 三环甾类激素核受体调节剂 |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| JP2008508314A (ja) | 2004-07-28 | 2008-03-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物 |
| TWI400239B (zh) | 2004-11-10 | 2013-07-01 | Incyte Corp | 內醯胺化合物及其作為醫藥品之用途 |
| HRP20120078T1 (hr) | 2006-10-31 | 2012-02-29 | Pfizer Products Inc. | Pirazolinski spojevi kao antagonisti mineralokortikoidnih receptora |
| US20100120736A1 (en) | 2007-03-29 | 2010-05-13 | N.V. Organon | Mineralocorticoid Receptor Antagonists |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| US20100292233A1 (en) | 2008-01-25 | 2010-11-18 | Arena Pharmaceuticals, Inc. | Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists |
| WO2010104721A1 (en) | 2009-03-12 | 2010-09-16 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
-
2008
- 2008-12-02 TW TW097146779A patent/TWI431010B/zh not_active IP Right Cessation
- 2008-12-02 PE PE2008002008A patent/PE20091057A1/es not_active Application Discontinuation
- 2008-12-03 CL CL2008003600A patent/CL2008003600A1/es unknown
- 2008-12-03 AR ARP080105263A patent/AR069554A1/es unknown
- 2008-12-09 MX MX2010006911A patent/MX2010006911A/es active IP Right Grant
- 2008-12-09 UA UAA201007627A patent/UA100131C2/uk unknown
- 2008-12-09 SI SI200830852T patent/SI2235007T1/sl unknown
- 2008-12-09 US US12/330,539 patent/US7994164B2/en not_active Expired - Fee Related
- 2008-12-09 ES ES12185389.9T patent/ES2459318T3/es active Active
- 2008-12-09 AU AU2008343524A patent/AU2008343524B2/en not_active Ceased
- 2008-12-09 WO PCT/US2008/085997 patent/WO2009085584A1/en not_active Ceased
- 2008-12-09 ES ES08866835T patent/ES2396605T3/es active Active
- 2008-12-09 NZ NZ586300A patent/NZ586300A/en not_active IP Right Cessation
- 2008-12-09 EP EP12185389.9A patent/EP2537845B1/en active Active
- 2008-12-09 BR BRPI0820805-0A patent/BRPI0820805A2/pt not_active IP Right Cessation
- 2008-12-09 JP JP2010539618A patent/JP5562866B2/ja not_active Expired - Fee Related
- 2008-12-09 PT PT88668355T patent/PT2235007E/pt unknown
- 2008-12-09 EA EA201070762A patent/EA017668B1/ru not_active IP Right Cessation
- 2008-12-09 RS RS20120541A patent/RS52594B/sr unknown
- 2008-12-09 PL PL08866835T patent/PL2235007T3/pl unknown
- 2008-12-09 MY MYPI20102867 patent/MY150474A/en unknown
- 2008-12-09 CA CA2710409A patent/CA2710409C/en not_active Expired - Fee Related
- 2008-12-09 DK DK08866835.5T patent/DK2235007T3/da active
- 2008-12-09 KR KR1020107013601A patent/KR101254382B1/ko not_active Expired - Fee Related
- 2008-12-09 HR HRP20120916AT patent/HRP20120916T1/hr unknown
- 2008-12-09 EP EP08866835A patent/EP2235007B1/en active Active
- 2008-12-09 CN CN200880121527.2A patent/CN101903377B/zh not_active Expired - Fee Related
-
2010
- 2010-06-14 MA MA32909A patent/MA31910B1/fr unknown
- 2010-06-14 IL IL206353A patent/IL206353A/en not_active IP Right Cessation
- 2010-06-15 ZA ZA2010/04257A patent/ZA201004257B/en unknown
- 2010-06-16 CO CO10072532A patent/CO6300953A2/es not_active Application Discontinuation
- 2010-06-17 EC EC2010010266A patent/ECSP10010266A/es unknown
- 2010-06-17 DO DO2010000185A patent/DOP2010000185A/es unknown
- 2010-06-17 GT GT201000179A patent/GT201000179A/es unknown
- 2010-06-18 TN TN2010000292A patent/TN2010000292A1/fr unknown
-
2012
- 2012-07-17 EC ECSP12012048 patent/ECSP12012048A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069554A1 (es) | Compuesto triciclico de amino benzoimidazol | |
| CL2008001636A1 (es) | Compuestos derivados de bencimidazol, antagonistas de los receptores de angiotensina ii de tipo 1; proceso de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica de los compuestos; y su uso para tratar la hipertension, insuficiencia cardiaca. | |
| EA201001724A1 (ru) | Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов | |
| EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
| MA34916B1 (fr) | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques | |
| EA201171361A1 (ru) | Ингибиторы внешнего медуллярного калиевого канала почек | |
| EA200900048A1 (ru) | Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина | |
| MA32812B1 (fr) | Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| CL2008000059A1 (es) | Compuestos derivados de espiropiperidina-glicinamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hipertension, dismenorrea, fallo cardiaco cronico, ansiedad, t | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| EA201190207A1 (ru) | Соединения для лечения метаболических расстройств | |
| ATE404555T1 (de) | Neue mch-rezeptorantagonisten | |
| EA201000283A1 (ru) | Новые гетероциклические соединения в качестве антагонистов метаботропных глутаматных рецепторов 5-го подтипа (мглу5) | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| AR049681A1 (es) | Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas | |
| PE20110103A1 (es) | Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas | |
| ECSP088398A (es) | Compuestos tricíclicos útiles como agonistas de receptores de oxitocina | |
| CO6300937A2 (es) | Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu | |
| CL2007003504A1 (es) | Compuestos derivados de indol-2-il-carbonil-piperidina, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea, hipertension, fallo cardiaco cronico y trastornos depresivos, ent | |
| EA201171125A1 (ru) | Антагонист минералокортикоидного рецептора и способы его применения | |
| CL2008001162A1 (es) | Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |